Aprea Therapeutics, Inc. (APRE)
$3.8
+0.36 (+10.47%)
Rating:
Recommendation:
-
| Symbol | APRE |
|---|---|
| Price | $3.8 |
| Beta | 0.000 |
| Volume Avg. | 0.01M |
| Market Cap | 14.180M |
| Shares () | - |
| 52 Week Range | 0.474-25.8 |
| 1y Target Est | - |
| DCF Unlevered | APRE DCF -> | |
|---|---|---|
| DCF Levered | APRE LDCF -> | |
| ROE | -1457.11% | Strong Sell |
| ROA | -725.75% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 12.48% | Neutral |
| P/E | -0.07 | Neutral |
| P/B | 0.25 | Neutral |
Latest APRE news
About
Download (Excel)Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.